Field Trip Health

Field Trip Health was a Canadian publicly traded ketamine-assisted psychotherapy company founded in 2019 that operated clinics across North America and Europe while developing FT-104, a shorter-duration psilocybin analog, before a 2023 financial restructuring under Canada's Companies' Creditors Arrangement Act. Its drug development assets were spun off as Reunion Neuroscience (which raised $103M Series A in 2024) while its US clinic network was acquired by Stella and its Canadian clinics by the Canadian Centre for Psychedelic Healing.